The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sushma Kakani
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 6.4 pts more than Nifty Microcap 250 and 5.5 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Sushma Kakani, a promoter of Godavari Drugs Ltd, acquired 4,23,000 convertible warrants through a preferential allotment on 18 March 2026, as disclosed under SEBI Takeover Regulations. Before the acquisition, she held 11,55,000 equity shares (15.34% of voting capital); after adding the warrants, her total potential holding rises to 15,78,000 units (11.40% of equity, 12.64% on a fully diluted basis). The company's equity share capital expanded significantly from 75,30,500 shares to 1,01,27,435 shares as part of the preferential issue, with total diluted share capital now standing at 1,24,87,500 shares. The warrants give the promoter the right to convert into equity shares at a later date, increasing her eventual economic interest in the company.
This signals promoter confidence and continued commitment to the company, but the preferential issue has materially diluted existing shareholders' stakes. Existing equity holders' percentage holding drops sharply, though the promoter's absolute potential holding has increased.